Mariner
KRYS icon

Mariner’s Krystal Biotech KRYS Stock Holding History

Mariner’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$271K Sell
1,048
-3,272
-76% -$871K ﹤0.01% 2956
2025
Q4 		$1.07M Sell
4,320
-285
-6% -$60K ﹤0.01% 1903
2025
Q3 		$813K Buy
4,605
+350
+8% +$52.4K ﹤0.01% 2067
2025
Q2 		$585K Buy
4,255
+618
+17% +$90.8K ﹤0.01% 2204
2025
Q1 		$656K Buy
3,637
+262
+8% +$44.1K ﹤0.01% 1978
2024
Q4 		$529K Sell
3,375
-247
-7% -$43.8K ﹤0.01% 2152
2024
Q3 		$658K Buy
3,622
+325
+10% +$62.7K ﹤0.01% 1923
2024
Q2 		$605K Sell
3,297
-479
-13% -$80.4K ﹤0.01% 1906
2024
Q1 		$672K Buy
3,776
+16
+0.4% +$2.22K ﹤0.01% 1809
2023
Q4 		$466K Sell
3,760
-130
-3% -$14.4K ﹤0.01% 1978
2023
Q3 		$451K Buy
3,890
+64
+2% +$7.81K ﹤0.01% 1850
2023
Q2 		$449K Sell
3,826
-1,124
-23% -$115K ﹤0.01% 1819
2023
Q1 		$396K Sell
4,950
-195
-4% -$15.3K ﹤0.01% 1851
2022
Q4 		$408K Buy
5,145
+1,136
+28% +$84.3K ﹤0.01% 1786
2022
Q3 		$279K Buy
+4,009
New +$290K ﹤0.01% 1824

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mariner's KRYS Position: Q1 2026 in Review

Mariner reduced its Krystal Biotech (KRYS) stake by 76% in Q1 2026, selling an estimated $871K and leaving 1,048 shares worth $271K. The position accounts for ﹤0.01% of the portfolio, ranked #2956.

Mariner first reported a position in KRYS in Q3 2022 and has held it in 15 quarters since. The position peaked at $1.07M in Q4 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Mariner held 1,048 shares of Krystal Biotech worth $271K as of Q1 2026.
  • Mariner sold 3,272 Krystal Biotech shares in Q1 2026, an estimated $871K.
  • Krystal Biotech made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #2956 holding.
  • Mariner first reported a position in Krystal Biotech in Q3 2022 and has held it in 15 quarters since.
  • Mariner's Krystal Biotech position peaked at $1.07M in Q4 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.